首都医科大学学报 ›› 2024, Vol. 45 ›› Issue (2): 296-301.doi: 10.3969/j.issn.1006-7795.2024.02.018

• 基础研究 • 上一篇    下一篇

抗OX40/EGFR双特异性抗体的制备和活性鉴定

晋瑞娜1,  边海波2,  张晓敏1,  杨  帆1,  王晚萍2*   

  1. 1.长治市人民医院中心实验室,山西长治 046000; 2.长治市人民医院呼吸与危重症学科,山西长治 046000
  • 收稿日期:2023-09-11 出版日期:2024-04-21 发布日期:2024-04-25
  • 通讯作者: 王晚萍 E-mail:wanping1124@163.com
  • 基金资助:
    山西省自然科学基金面上项目(20210302124004), 山西省卫健委项目(2022024)。

Construction and activity identification of anti-OX40/anti-EGFR bispecific antibody

Jin Ruina1, Bian Haibo2, Zhang Xiaomin1, Yang Fan1, Wang Wanping2*   

  1. 1.Department of Central Laboratory, Changzhi Peoples Hospital, Changzhi 046000, Shanxi Province, China; 2.Department of Respiratory and Critical Care Medicine, Changzhi Peoples Hospital, Changzhi 046000, Shanxi Province, China
  • Received:2023-09-11 Online:2024-04-21 Published:2024-04-25
  • Supported by:
    This study was supported by Natural Science Foundation of Shanxi Province( 20210302124004),Health Commission of Shanxi Province (2022024).

摘要: 目的  构建同时靶向表皮生长因子受体(epidermal growth factor receptor,EGFR)和OX40的双特异性抗体,并在体外初步验证其对T细胞的特异性激活作用。方法  构建抗OX40/EGFR双特异性抗体的真核表达载体,转染293F细胞进行表达和纯化。构建外源表达OX40和EGFR的HEK293T细胞,利用流式细胞术分析双抗与靶蛋白表达细胞的结合活性。并利用Jurkat-OX40-NF-κB-GFP报告细胞,验证双特异性抗体对报告细胞的激活活性。通过酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测外周血单个核细胞(peripheral blood mononuclear cell,PBMC)的白细胞介素-2(interleukin-2,IL-2)和γ-干扰素(interferon-γ,IFN-γ)分泌,进一步验证抗OX40/EGFR双抗对原代T细胞的激活。结果  成功构建并且纯化了抗OX40/EGFR双特异性抗体,并且验证了该双抗可以特异性地结合表达EGFR和OX40的HEK293T细胞。在表达EGFR的A549肺癌细胞介导的交联作用下,该双特异性抗体较OX40单抗更强地激活OX40-NF-κB报告细胞,并且促进PBMC分泌IL-2和IFN-γ细胞因子。结论  抗OX40/EGFR双特异性抗体构建成功,可同时识别OX40和EGFR受体并激活肿瘤特异性T细胞。

关键词: OX40, 表皮生长因子受体, 双特异性抗体, 癌症, T细胞激活

Abstract: Objective  To construct a bispecific antibody targeting epidermal growth factor receptor(EGFR) and OX40 and evaluate the function for tumor-specific T cell activation. Methods  The gene of anti-OX40/anti-EGFR bispecific antibody was cloned into eukaryotic expression vector, and then the constructed vector were transfected to 293F cells for the bispecific antibody purification. The binding activity of anti-OX40/anti-EGFR bispecific antibody with the cells expressing target proteins  were detected by flow cytometry. To identify the activation of T cells mediated by anti-OX40/anti-EGFR bispecific antibody, the activation of NF-κB signal activation was evaluated by Jurkat-OX40-NF-κB-GFP reporter cells and the activation of primary T cells was detected by interleukin-2(IL-2) and interferon-γ(IFN-γ) secretion of peripheral blood mononuclear cell(PBMC). Results  Anti-OX40/anti-EGFR bispecific antibody was successfully constructed and purified, and its binding ability to HEK293 cells expressing OX40 and EGFR was verified. Jurkat-OX40-NF-κB-GFP reporter cells were activated by the bispecific antibody with the crosslinking of A549 cells. Further, the anti-OX40/anti-EGFR bispecific antibody promoted the secretion of IL-2 and IFN-γ of PBMC. Conclusion  Anti-OX40/anti-EGFR bispecific antibody was successfully constructed which could specifically recognize OX40 and EGFR and activate tumor specific T cells.

Key words: OX40, epidermal growth factor receptor (EGFR), bispecific antibody (BsAb), cancer, T cell activation

中图分类号: